Claims
- 1. A method for affecting intraocular pressure in an eye of a patient, said method comprising administering to the eye a compound which specifically modulates the ATP-sensitive K.sup.+ channel present in an ophthalmically acceptable carrier in an amount effective to change said intraocular pressure.
- 2. A method as in claim 1, wherein the compound is administered by topical application to the eye.
- 3. A method as in claim 1, wherein the compound is administered by injection into the anterior chamber.
- 4. A method as in claim 1, wherein the compound is administered using an ocular insert.
- 5. A method as in claim 1, wherein the ATPase compound is an ATP-sensitive K.sup.+ channel inhibitor, whereby intraocular pressure is decreased.
- 6. A method as in claim 5, wherein the compound is selected for the group consisting of glybenclamide, glipizide, tolbutamide, and tolazamide, chlorpropamide or other sulfonylureas, 2,3-butanedione, 5-hydroxdecanoic acid, and therapeutically equivalent salts or derivatives thereof.
- 7. A method as in claim 5, wherein the patient suffers from glaucoma.
- 8. A method as in claim 1, wherein the compound is an ATP-sensitive K.sup.+ channel potentiator, whereby an intraocular pressure is increased.
- 9. A method as in claim 8, wherein the compound is diazoxide or a therapeutically equivalent salt or derivative thereof.
- 10. A method as in claim 7, wherein the patient suffers from hypotonia.
- 11. A method as in claim 1, wherein the compound is administered in single dosages having from 50 .mu.g to 2 mg of the compound per dosage.
- 12. A method as in claim 11, wherein the dosages are administered from 1 to 4 times per day.
Parent Case Info
The present application is a continuation-in-part of application Ser. No. 08/466,162, filed on Jun. 6, 1995, now abandoned , which was a continuation of application Ser. No. 08/096,799, filed on Jul. 23, 1993, now U.S. Pat. No. 5,629,345, the full disclosures of which are incorporated herein by reference.
US Referenced Citations (54)
Foreign Referenced Citations (31)
Number |
Date |
Country |
885496 |
Jan 1981 |
BEX |
0080779 |
Jun 1983 |
EPX |
0086126 |
Aug 1983 |
EPX |
0087378 |
Aug 1983 |
EPX |
0089037 |
Sep 1983 |
EPX |
0090516 |
Oct 1983 |
EPX |
0113910 |
Jul 1984 |
EPX |
0130109 |
Jan 1985 |
EPX |
0132190 |
Jan 1985 |
EPX |
0175266 |
Mar 1986 |
EPX |
0180994 |
May 1986 |
EPX |
0189801 |
Aug 1986 |
EPX |
0235544 |
Sep 1987 |
EPX |
0329903 |
Aug 1989 |
EPX |
0338507 |
Oct 1989 |
EPX |
0370852 |
May 1990 |
EPX |
0403158 |
Dec 1990 |
EPX |
0403360 |
Dec 1990 |
EPX |
0437030 |
Jul 1991 |
EPX |
0459568 |
Dec 1991 |
EPX |
2585574 |
Jul 1985 |
FRX |
2593395 |
Jan 1986 |
FRX |
01-246220 |
Oct 1989 |
JPX |
02-262528 |
Oct 1990 |
JPX |
WO 8300043 |
Jan 1983 |
WOX |
WO 8600896 |
Feb 1986 |
WOX |
WO 8703583 |
Jun 1987 |
WOX |
WO 8703584 |
Jun 1987 |
WOX |
WO 8910757 |
Nov 1989 |
WOX |
WO 9002124 |
Mar 1990 |
WOX |
WO 9006111 |
Jun 1990 |
WOX |
Non-Patent Literature Citations (4)
Entry |
The Merck Index, Eleventh Edition (1989). |
Leibowitz et al., Surv. Ophthamol. 24 (Suppl):366-400 (1980). |
Leske, Am. J. Epidemiol. 118:166-191 (1983). |
Minckler et al., Am. J. Ophthamol. 104:168-173 (1987). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
096799 |
Jul 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
466162 |
Jun 1995 |
|